Is INMB or SPRB more profitable?

INmune Bio's return on equity of -103.03% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Spruce Biosciences N/A -155.40% -101.67%

Does the media refer more to INMB or SPRB?

In the previous week, INmune Bio had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 4 mentions for INmune Bio and 2 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.94 beat INmune Bio's score of 0.62 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ENLV or INMB more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% INmune Bio N/A -103.03% -77.66%

Is CGTX or INMB more profitable?

Cognition Therapeutics' return on equity of -72.68% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% INmune Bio N/A -103.03% -77.66%

Does the media prefer CGTX or INMB?

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 0.78 beat INmune Bio's score of 0.62 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend INMB or TLSA?

INmune Bio currently has a consensus price target of $8.00, indicating a potential upside of 374.78%. Given INmune Bio's stronger consensus rating and higher probable upside, research analysts clearly believe INmune Bio is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, INMB or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than INmune Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 895.75 -$45.93M -$1.67 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is INMB or TLSA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Tiziana Life Sciences N/A N/A N/A

Does the media refer more to INMB or TLSA?

In the previous week, INmune Bio had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 4 mentions for INmune Bio and 3 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.63 beat INmune Bio's score of 0.62 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADCT or INMB?

In the previous week, ADC Therapeutics and ADC Therapeutics both had 4 articles in the media. INmune Bio's average media sentiment score of 0.62 beat ADC Therapeutics' score of 0.10 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

INmune Bio (INMB) Competitors

$1.68 +0.06 (+3.37%)

As of 12:35 PM Eastern

Compare

INMB vs. SPRB, ENLV, CGTX, TLSA, and ADCT

Should you buy INmune Bio stock or one of its competitors? MarketBeat compares INmune Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INmune Bio include Spruce Biosciences (SPRB), Enlivex Therapeutics (ENLV), Cognition Therapeutics (CGTX), Tiziana Life Sciences (TLSA), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry.

How does INmune Bio compare to Spruce Biosciences?

INmune Bio (NASDAQ:INMB) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Spruce Biosciences has higher revenue and earnings than INmune Bio. Spruce Biosciences is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	895.75	-$45.93M	-$1.67	N/A
Spruce Biosciences	$4.91M	30.06	-$38.97M	-$36.60	N/A

INmune Bio currently has a consensus target price of $8.00, indicating a potential upside of 374.78%. Spruce Biosciences has a consensus target price of $163.00, indicating a potential upside of 203.74%. Given INmune Bio's stronger consensus rating and higher possible upside, analysts plainly believe INmune Bio is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

INmune Bio has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.11, suggesting that its share price is 211% more volatile than the broader market.

In the previous week, INmune Bio had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 4 mentions for INmune Bio and 2 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.94 beat INmune Bio's score of 0.62 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

INmune Bio's return on equity of -103.03% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Spruce Biosciences	N/A	-155.40%	-101.67%

Summary

INmune Bio beats Spruce Biosciences on 10 of the 16 factors compared between the two stocks.

How does INmune Bio compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Enlivex Therapeutics' return on equity of 248.08% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
INmune Bio	N/A	-103.03%	-77.66%

Enlivex Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market. Comparatively, INmune Bio has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 21.4% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, INmune Bio had 3 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 4 mentions for INmune Bio and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.93 beat INmune Bio's score of 0.62 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Enlivex Therapeutics	Positive
INmune Bio	Positive

Enlivex Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 2,900.00%. INmune Bio has a consensus target price of $8.00, suggesting a potential upside of 374.78%. Given Enlivex Therapeutics' higher possible upside, equities research analysts plainly believe Enlivex Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Enlivex Therapeutics has higher earnings, but lower revenue than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
INmune Bio	$50K	895.75	-$45.93M	-$1.67	N/A

Summary

Enlivex Therapeutics beats INmune Bio on 8 of the 14 factors compared between the two stocks.

How does INmune Bio compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Cognition Therapeutics presently has a consensus target price of $3.33, suggesting a potential upside of 188.60%. INmune Bio has a consensus target price of $8.00, suggesting a potential upside of 374.78%. Given INmune Bio's stronger consensus rating and higher probable upside, analysts plainly believe INmune Bio is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Cognition Therapeutics has higher earnings, but lower revenue than INmune Bio. Cognition Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
INmune Bio	$50K	895.75	-$45.93M	-$1.67	N/A

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 0.78 beat INmune Bio's score of 0.62 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cognition Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, INmune Bio has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cognition Therapeutics' return on equity of -72.68% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
INmune Bio	N/A	-103.03%	-77.66%

Summary

Cognition Therapeutics beats INmune Bio on 8 of the 14 factors compared between the two stocks.

How does INmune Bio compare to Tiziana Life Sciences?

INmune Bio (NASDAQ:INMB) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

12.7% of INmune Bio shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, INmune Bio had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 4 mentions for INmune Bio and 3 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.63 beat INmune Bio's score of 0.62 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tiziana Life Sciences' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Tiziana Life Sciences	N/A	N/A	N/A

Tiziana Life Sciences has lower revenue, but higher earnings than INmune Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	895.75	-$45.93M	-$1.67	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

INmune Bio has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

INmune Bio currently has a consensus price target of $8.00, indicating a potential upside of 374.78%. Given INmune Bio's stronger consensus rating and higher probable upside, research analysts clearly believe INmune Bio is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

INmune Bio beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks.

How does INmune Bio compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

INmune Bio has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
INmune Bio	N/A	-103.03%	-77.66%

ADC Therapeutics currently has a consensus target price of $6.25, suggesting a potential upside of 465.61%. INmune Bio has a consensus target price of $8.00, suggesting a potential upside of 374.78%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by company insiders. Comparatively, 21.4% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ADC Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, INmune Bio has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

INmune Bio has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.73	-$142.62M	-$1.05	N/A
INmune Bio	$50K	895.75	-$45.93M	-$1.67	N/A

In the previous week, ADC Therapeutics and ADC Therapeutics both had 4 articles in the media. INmune Bio's average media sentiment score of 0.62 beat ADC Therapeutics' score of 0.10 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADC Therapeutics and INmune Bio tied by winning 8 of the 16 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMB vs. The Competition

Export

Metric	INmune Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$44.44M	$3.66B	$6.80B	$12.58B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-1.00	21.54	27.48	25.45
Price / Sales	895.75	343.84	541.47	103.18
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	1.91	8.73	10.97	6.65
Net Income	-$45.93M	$23.87M	$3.57B	$336.83M
7 Day Performance	24.81%	3.76%	2.80%	3.00%
1 Month Performance	21.22%	3.79%	1.93%	0.56%
1 Year Performance	-19.38%	67.44%	36.49%	30.42%

INmune Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMB INmune Bio	1.7696 of 5 stars	$1.69 +3.4%	$8.00 +374.8%	-29.4%	$44.44M	$50K	N/A	10	News Coverage
SPRB Spruce Biosciences	3.0861 of 5 stars	$53.19 -2.8%	$163.00 +206.4%	+893.1%	$146.84M	N/A	N/A	20
ENLV Enlivex Therapeutics	3.3854 of 5 stars	$0.63 +0.6%	$16.50 +2,531.6%	-50.9%	$145.51M	N/A	N/A	70	Gap Up
CGTX Cognition Therapeutics	3.7505 of 5 stars	$1.61 -4.3%	$3.33 +107.4%	+271.2%	$143.83M	N/A	N/A	20	Gap Up
TLSA Tiziana Life Sciences	0.5005 of 5 stars	$1.10 -4.3%	N/A	-19.0%	$139.99M	N/A	N/A	8	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMB) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INmune Bio (INMB) Competitors

INMB vs. SPRB, ENLV, CGTX, TLSA, and ADCT

How does INmune Bio compare to Spruce Biosciences?

Summary

How does INmune Bio compare to Enlivex Therapeutics?

Summary

How does INmune Bio compare to Cognition Therapeutics?

Summary

How does INmune Bio compare to Tiziana Life Sciences?

Summary

How does INmune Bio compare to ADC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INmune Bio (INMB) Competitors

INMB vs. SPRB, ENLV, CGTX, TLSA, and ADCT

How does INmune Bio compare to Spruce Biosciences?

Which has preferable valuation and earnings, INMB or SPRB?

Do analysts prefer INMB or SPRB?

Which has more volatility & risk, INMB or SPRB?

Does the media refer more to INMB or SPRB?

Do insiders & institutionals have more ownership in INMB or SPRB?

Is INMB or SPRB more profitable?

Summary

How does INmune Bio compare to Enlivex Therapeutics?

Is ENLV or INMB more profitable?

Which has more volatility & risk, ENLV or INMB?

Do institutionals & insiders have more ownership in ENLV or INMB?

Does the media prefer ENLV or INMB?

Do analysts recommend ENLV or INMB?

Which has higher valuation and earnings, ENLV or INMB?

Summary

How does INmune Bio compare to Cognition Therapeutics?

Do analysts recommend CGTX or INMB?

Which has stronger earnings and valuation, CGTX or INMB?

Does the media prefer CGTX or INMB?

Which has more risk & volatility, CGTX or INMB?

Do insiders and institutionals hold more shares of CGTX or INMB?

Is CGTX or INMB more profitable?

Summary

How does INmune Bio compare to Tiziana Life Sciences?

Do insiders & institutionals have more ownership in INMB or TLSA?

Does the media refer more to INMB or TLSA?

Is INMB or TLSA more profitable?

Which has preferable earnings and valuation, INMB or TLSA?

Which has more risk and volatility, INMB or TLSA?

Do analysts recommend INMB or TLSA?

Summary

How does INmune Bio compare to ADC Therapeutics?

Is ADCT or INMB more profitable?

Do analysts rate ADCT or INMB?

Do institutionals and insiders have more ownership in ADCT or INMB?

Which has more volatility & risk, ADCT or INMB?

Which has better earnings and valuation, ADCT or INMB?

Does the media prefer ADCT or INMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools